Back to Search
Start Over
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
- Source :
- Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-10 (2017)
- Publication Year :
- 2017
- Publisher :
- BMC, 2017.
-
Abstract
- Abstract Background Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by lysosomal acid alpha-glucosidase (GAA) deficiency that ultimately results in mobility loss and respiratory failure. Current enzyme replacement therapy with recombinant human (rh)GAA has demonstrated efficacy in subjects with late-onset Pompe disease. However, long-term effects of rhGAA on pulmonary function have not been observed, likely related to inefficient delivery of rhGAA to skeletal muscle lysosomes and associated deficits in the central nervous system. To address this limitation, reveglucosidase alfa, a novel insulin-like growth factor 2 (IGF2)-tagged GAA analogue with improved lysosomal uptake, was developed. This study evaluated the pharmacokinetics, safety, and exploratory efficacy of reveglucosidase alfa in 22 subjects with late-onset Pompe disease who were previously untreated with rhGAA. Results Reveglucosidase alfa plasma concentrations increased linearly with dose, and the elimination half-life was
Details
- Language :
- English
- ISSN :
- 17501172
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Orphanet Journal of Rare Diseases
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0f42cc539c044d06b2948b37cb169a2e
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s13023-017-0693-2